TransRadial Education and Therapeutics (TREAT): Shifting the balance of safety and efficacy of antithrombotic agents in percutaneous coronary intervention: A report from the Cardiac Safety Research Consortium
Creators: name: Fadiran, Emmanuel O.
name: Krucoff, Mitchell W.
name: Jacobs, Alice K.
name: Hess, Connie N.
name: Collet, Jean Philippe
name: Eloff, Benjamin C.
name: Anstrom, Kevin J.
name: Miller, Julie M.
name: Tavris, Dale R.
name: Kaul, Prashant
name: Tsai, Thomas T.
name: Rutledge, David R.
name: Rao, Sunil V.
name: Holmes, David R.
name: White, Roseann M.
name: Bertrand, Olivier F.
name: Gilchrist, Ian C.
name: Effron, Mark B.
name: Farb, Andrew
name: Peterson, Eric D.
name: Newby, L. Kristin
name: Kong, David F.
Publisher: name: The University of North Carolina at Chapel Hill University Libraries
Year: 2013

description: Appendix Participants from Academia and Clinical Practice: Alexandre Abizaid, MD, PhD; Kevin J. Anstrom, PhD; Olivier F. Bertrand, MD, PhD; David Cohen, MD; Donald Cutlip, MD; Connie N. Hess, MD; David R. Holmes, MD; Alice K. Jacobs, MD; Sanjit Jolly, MD; Prashant Kaul, MD; Spencer King, MD; David F. Kong, MD; Mitchell W. Krucoff, MD; Venu Menon, MD; John Messenger, MD; Julie M. Miller, MD; L. Kristin Newby, MD, MHS; Kari Niemelae, MD, PhD; Sharon-Lise Normand, PhD; Tejas M. Patel, MD, DM; Eric D. Peterson, MD, MPH; John Petersen, II, MD, MHS; Sunil V. Rao, MD; Jon R. Resar, MD; George Revtyak, MD; Shigeru Saito, MD; Jean-François Tanguay, MD; Ron Waksman, MD; Stephen D. Wiviott, MD; Chuntao Wu, MD, PhD. Participants from the US FDA: Daniel Canos, MPH; Hesha Duggirala, PhD; Benjamin C. Eloff, PhD; Emmanuel Fadiran, PhD; Andrew Farb, MD; Andrea Furia-Helms, MPH; Beverly Gallauresi, RN, MPH; John Laschinger, MD; Danica Marinac-Dabic, MD, PhD; Ameeta Parekh, PhD; Ellen Pinnow, MS; Synim N. Rivers, MPH; M. Marius Rozek; Tara A. Ryan, MD, MS, MBA; Vicki Seyfert-Margolis, PhD; Jeffrey Shuren, MD, JD; Mary R. Southworth, PharmD; Norman Stockbridge, MD, PhD; Dale R. Tavris, MD, MPH; Douglas Throckmorton, MD; Shaokui Wei, MD, MPH; Xu (Sherry) Yan, PhD. Participants from the American College of Cardiology: Ralph Brindis, MD; ToniAnn Cox, BA; Kathleen Hewitt, MSN; Dana Pinchotti; Laura Ritzenthaler; Thomas T. Tsai MD, MSc; Janet S. Wright. Participants from the European Society of Cardiology: Jean-Philippe Collet, MD. Participants from Society for Cardiovascular Angioplasty and Interventions: Ian C. Gilchrist, MD; Joel Harder, MBA. Participants from Cardiovascular Research Foundation: Roxana Mehran, MD. Participants from Industry: Gary Clifton, MBA; Sidney Cohen, MD; William Daley MD; Markus Dietrich, MD, PhD; Gina Eagle, MD; Mark B. Effron, MD; John Finkle, MD; Ruchira Glaser MD; Jerri Anne Johnson; Dina Justice; Stuart Keller; Matthew Killeen PhD; Patricia Knipper; Janine Lane; Jenny Lim, PhD; Roberto Lovick, PharmD; Tom Mahoney; Clive Meanwell, MD, PhD; Lorenz Muller; Funmi Oduolowu, PharmD; Charles Oh; Margaret Quattrocchi; James Rushworth; David R. Rutledge, PharmD; Anne Vosatka, MD, PhD; Mona M. Wahba; Govinda Weerakkody, PhD; Roseann M. White, MA; Kenneth J. Winters, MD; Theressa Wright, MD; Marjorie Zettler, PhD, MPH. Participants from the Coordinating Staff: Britt Barham; Lauren Beller; Laura Melton, PhD; Valarie Morrow, MD; RhaShawn Wells; Willette Wilkins MBA. Percutaneous coronary intervention (PCI) is an integral part of the treatment of coronary artery disease. The most common complication of PCI, bleeding, typically occurs at the vascular access site and is associated with short-term and long-term morbidity and mortality. Periprocedural bleeding also represents the primary safety concern of concomitant antithrombotic therapies essential for PCI success. Use of radial access for PCI reduces procedural bleeding and hence may change the risk profile and net clinical benefit of these drugs. This new drug-device safety interaction creates opportunities to advance the safe and effective use of antithrombotic agents during PCI. In June 2010 and March 2011, leaders from government, academia, professional societies, device manufacturing, and pharmaceutical industries convened for 2 think tank meetings. Titled TREAT I and II, these forums examined approaches to improve the overall safety of PCI by optimizing strategies for antithrombotic drug use and radial artery access. This article summarizes the content and proceedings of these sessions.